FINWIRES · TerminalLIVE
FINWIRES

Novartis Says Cosentyx Shows Sustained Remission in Phase 3 Trial

By

Novartis (NVS) said Wednesday new Cosentyx data from a late-stage trial in polymyalgia rheumatica showed a statistically significant, clinically meaningful difference in sustained remission rates against placebo and significant steroid sparing.

The effect of Cosentyx treatment was sustained through week 52, the company said, adding that the trial met all primary and secondary endpoints, and no new safety signals were identified.

Novartis said it has submitted Cosentyx for regulatory review in the US, EU, and Japan, with other filings expected to follow throughout 2026, it added.

Separately, Novartis Canada said it has reached an agreement with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Scemblix for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Price: $143.53, Change: $+0.05, Percent Change: +0.03%

Related Articles

Wire

Update: Nova Minerals Says New South Wales Court Approves New US Holding Entity Plan; Shares Fall 6%

(Updates to add stock movement in the headline and last paragraph)Nova Minerals (ASX:NVA) said the Supreme Court of New South Wales has approved its proposed schemes of arrangement, enabling newly formed Nova Minerals Corp to acquire all existing shares and Nasdaq-listed warrants and become the group's new US-based holding entity, according to an Australian bourse filing on Tuesday after market hours.The schemes are expected to take legal effect on Wednesday upon lodgment of the court orders with the Australian Securities and Investments Commission, after which the company shares are anticipated to be suspended from trading on the Australian Securities Exchange, the filing added.The company's shares fell around 6% in recent Wednesday trade.

ASX:NVA
Wire

Netskope Joins Anthropic's Project Glasswing to Spot Code Vulnerabilities

Netskope (NTSK) said late Tuesday it has joined Project Glasswing, an Anthropic initiative that uses the company's most advanced AI model, Mythos Preview, to identify vulnerabilities in software code at greater speed and scale.Netskope has access to Anthropic's Claude Mythos Preview and will share findings with the broader Glasswing coalition and the cybersecurity community as part of the effort.Netskope shares rose 3.1% in after-hours trading.

$NTSK
Wire

TETRA Technologies Launches $100 Million Common Stock Offering

TETRA Technologies (TTI) said Tuesday it commenced an underwritten public offering of $100 million of shares of common stock.The company said it expects to grant underwriters a 30-day option to buy up to an additional $15 million of shares to cover over-allotments.Proceeds will be used for general corporate purposes, including funding construction of its Arkansas bromine project, according to a statement.Shares of the company were down over 9% in extended trading.

$TTI